白血病、血管增生、癌症疫苗：藥劑開發策略分析

白血病、血管增生、癌症疫苗：藥劑開發策略分析 是由出版商BioSeeker Group AB在2012年01月所出版的。 這份英文市場調查報告書包含3510 Pages 價格從美金5175起跳。

簡介

本報告針對白血病的藥物開發策略與血管增生與癌症疫苗的機制、目的、影響分類為焦點，提供各藥劑目的策略、複合策略競爭基準、臨床實驗與分析計劃，目錄介紹如下。

第1章 白血病

• 本報告範圍
• 以最佳治療結果與投資回收率為前提的白血病標的治療藥物分析
• 新藥登場：開發階段分類白血病藥物目標策略
• 使用中的複合策略：複合策略分類競爭基準
• 白血病治療藥物適應症
• 臨床實驗與分析計劃：白血病臨床實驗競爭基準
• 免責事項
• 藥物索引
• 企業索引

第2章 血管形成

• 本報告範圍
• 以最佳治療結果與投資回收率為前提的治療目標
• 新藥登場：開發階段分類血管增生藥物目標策略
• 使用中的複合策略：複合策略分類競爭基準
• 藥物影響與血管增生的適應癌症
• 臨床實驗與分析計劃：調查人員競爭基準
• 免責事項
• 藥物索引
• 企業索引

第3章 癌症疫苗

• 本報告範圍
• 以最佳治療結果與投資回收率為前提的治療目標
• 新藥登場：開發階段分類癌症疫苗藥物目的策略
• 使用中的複合策略：複合策略分類競爭基準
• 藥物影響與癌症疫苗的癌症適應症
• 臨床實驗與分析計劃
• 免責事項
• 藥物索引
• 企業索引

目錄

Abstract

This triple analysis focuses on cancer drug development strategies in Leukemia and by the two mechanism/target/effect areas of Angiogenesis and Cancer Vaccines. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Table of Contents

Key Topics Covered:

Part I: Leukemia

• 5.1. The Scope of this Report
• 6. Consider the Therapeutic Target Among Leukemia Drugs for the Highest Therapeutic Outcome and Return on Investment (204 Drug Targets)
• 7. Emerging New Products to Established Ones: Drug Target Strategies of Leukemia Drugs by their Highest Stage of Development (193 Drug Target Strategies and 313 Leukemia Drugs)
• 8. Compound Strategies at Work: Competitive Benchmarking of Leukemia Drugs by Compound Strategy (8 Compound Strategies)
• 9. Selecting Subindication for Leukemia Drugs (8 Subindications of Leukemia)
• 10. Pipeline and Portfolio Planning: Competitive Benchmarking of the Leukemia Drug Pipeline by Investigator (186 Companies)
• 11. Disclaimer
• 12. Drug Index
• 13. Company Index

• Figures: Includes 6 Figures
• Tables: Includes 253 Tables
• Total Number of Pages: 1,147

Part II: Angiogenesis

• 5.1. The Scope of this Report
• 6. Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (174 Drug Targets)
• 7. Emerging New Products to Established Ones: Drug Target Strategies of Cancer Drugs Affecting Angiogenesis by their Highest Stage of Development (167 Drug Target Strategies and 239 Drugs)
• 8. Compound Strategies at Work: Competitive Benchmarking of Cancer Drugs Affecting Angiogenesis by Compound Strategy (7 Different Compound Strategies)
• 9. Selecting Cancer Indications for Angiogenesis Affecting Drugs in Oncology (64 Cancer Indications)
• 10. Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (148 Investigators)
• 10. Disclaimer
• 11. Drug Index
• 12. Company Index

• Figures: Includes 7 Figures
• Tables: Includes 300 Tables
• Total Number of Pages: 1227

Part III: Cancer Vaccines

• 5.1. The Scope of this Report
• 6. Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment (94 Drug Targets)
• 7. Emerging New Products to Established Ones: Drug Target Strategies of Cancer Vaccine Drugs by their Highest Stage of Development (91 Drug Target Strategies and 155 Cancer Vaccine Drugs)
• 8. Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy (7 Compound Strategies)
• 9. Selecting Cancer Indications for Cancer Vaccine Drugs (42 Cancer Indications)
• 10. Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Investigator (99 Investigators)
• 11. Disclaimer
• 12. Drug Index
• 13. Company Index

• Figures: Includes 6 Figures
• Tables: Includes 205 Tables
• Total Number of Pages: 659

Featured Companies:

This Report Includes the Following Companies:

• 3M Pharmaceuticals
• 4SC
• Abbott
• Abiogen
• Abraxis BioScience
• AC Immune
• Acceleron Pharma
• Access
• ACT Biotech
• Actinium Pharmaceuticals
• Active Biotech
• Adaptimmune
• Adherex
• Aduro BioTech
• Advanced Cancer Therapeutics
• Advantagene
• Advaxis
• Advenchen
• AEgera
• Aeterna Zentaris
• Agennix
• Agenus
• Aida Pharmaceuticals
• Akela Pharma
• Alexion
• Alfa Wassermann
• Alnylam
• AlphaVax
• Altor BioScience
• Ambit Biosciences
• Ambrilia Biopharma
• Amgen
• Amphora
• Angiogen
• Angiogenex
• Angstrom Pharmaceuticals
• Ansaris
• Antisoma
• Apthera
• Arana Therapeutics
• Arca biopharma
• Ariad
• Arno Therapeutics
• ArQule
• Array BioPharma
• Asahi Kasei Pharma
• Ascenta Therapeutics
• Astellas
• Astex Therapeutics
• AstraZeneca
• Attenuon
• Austrianova
• AVI BioPharma
• Bavarian Nordic
• Bayer
• Bellicum Pharmaceuticals
• Bio-Path Holdings
• BioAlliance Pharma
• BioAxone
• Biocompatibles
• BioCryst Pharmaceuticals
• Bioenvision
• Biogen Idec
• BioSante
• Biostar
• Bioton
• BioVex
• Boehringer Ingelheim
• Bolder BioTechnology
• Bristol-Myers Squibb
• BTG
• Cadila
• Callisto Pharmaceuticals
• Cancer Research Technology
• CDG Therapeutics
• Celator Pharmaceuticals
• Celecure
• Celera
• Celgene
• Cell Genesys
• Cell Therapeutics
• CellCeutix
• Celldex Therapeutics
• Cellmid
• Cephalon
• CG Therapeutics
• ChemoCentryx
• Chemokine Therapeutics
• China Sky One Medical
• Choongwae
• Circadian Technologies
• CJ Corp
• Clavis Pharma
• Cornerstone Pharmaceuticals
• Cosmo Pharmaceuticals
• CSL
• Cue Biotech
• Curacyte
• CureTech
• Curis
• Cyclacel
• Cylene Pharmaceuticals
• CytImmune Sciences
• Cytochroma
• Cytokinetics
• Daiichi Sankyo
• Dainippon Sumitomo Pharma
• Dara Biosciences
• Deciphera Pharmaceuticals
• Dendreon
• DeveloGen
• DiaMedica
• Dong-A
• Dyax
• Eisai
• Eleos
• Eli Lilly
• Emergent BioSolutions
• Endocyte
• EntreMed
• Enzon
• Epeius Biotechnologies
• EpiCept
• Epizyme
• Erimos
• Esperance Pharmaceuticals
• Exelixis
• ExonHit Therapeutics
• Facet Biotech
• Five Prime Therapeutics
• GammaCan
• Gemin X Biotechnologies
• Genencor
• Genentech
• Generex
• Genmab
• GenOdyssee Pharmaceuticals
• Genta
• GENTICEL
• Genzyme
• Geron
• Gilead Sciences
• GlaxoSmithKline
• Gliknik
• GlobeImmune
• GlycoGenesys
• GlycoMimetics
• Gradalis
• Green Cross
• Hanmi
• Hayashibara
• Heber Biotec
• Hoffmann-La Roche
• Hy BioPharma
• Ichor Medical Systems
• Idera Pharmaceuticals
• IDM Pharma
• IkerChem
• ImClone Systems
• Immune Pharmaceuticals
• ImmunoCellular Therapeutics
• Immunocore
• ImmunoFrontier
• ImmunoGen
• Immunomedics
• Immunotope
• ImmuPharma
• Incyte Corporation
• InDex Pharmaceuticals
• Inex
• Innate Pharma
• Innovive
• Inovio
• Insys Therapeutics
• Intas Biopharmaceuticals
• Introgen Therapeutics
• ISA Pharmaceuticals
• Isis Pharmaceuticals
• Italfarmaco
• Johnson & Johnson
• KAI Pharmaceuticals
• KaloBios
• Kanisa
• Karus Therapeutics
• Kinex
• Kirin Pharma
• Kringle Pharma
• Kyowa Hakko Kirin
• Lee' s Pharmaceutical
• Leo
• LFB Biotechnologies
• LG Life Sciences
• Ligand
• Lorus Therapeutics
• MAT Biopharma
• MaxCyte
• MaxoCore Pharmaceuticals
• Meda
• Medical Marketing International
• MediGene
• Memgen
• Menarini
• Merck & Co
• Merck KGaA
• Mersana Therapeutics
• MethylGene
• Micromet
• MolMed
• Mologen
• Morvus Technology
• Nemod Biotherapeutics
• Neovacs
• Nereus Pharmaceuticals
• Nerviano Medical Sciences
• NewSouth Innovations
• NIH
• Nippon Shinyaku
• Non-industrial source
• Northwest Biotherapeutics
• Novartis
• NovaRx
• Novelix
• Novogen
• Oasmia
• OncoMune
• Onconova
• OncoTherapy Science
• Oncothyreon
• Oncovir
• Onyvax
• OSI Pharmaceuticals
• Otsuka
• Oxford BioMedica
• OXiGENE
• Pepscan Systems
• Pepscan Therapeutics
• PepTx
• Peregrine Pharmaceuticals
• Pfizer
• Pharmacopeia
• Pharmacyclics
• PharmaMar
• Pharmexa
• Pharminox
• Philogen
• PhiloGene
• PIERIS Proteolab
• Pierre Fabre
• Piramal
• Portola Pharmaceuticals
• Prima Biomed
• Prochon Biotech
• Progen
• Progenics Pharmaceuticals
• ProMetic Life Sciences
• Protein Sciences
• Protherics
• PTC Therapeutics
• Radient Pharmaceuticals
• Reata Pharmaceuticals
• Receptor BioLogix
• Regeneron
• Reliance Life Sciences
• responsif
• Rexahn
• Rigel
• Sangamo BioSciences
• Sanofi-Aventis
• Santaris Pharma
• Sareum
• SBI Biotech
• SBIO
• Scancell
• SciClone Pharmaceuticals
• Seattle Genetics
• Semafore Pharmaceuticals
• Sepal Pharma
• Servier
• Shenogen
• Shire
• Sidus
• Simcere Pharmaceuticals
• Southern Research Institute
• Spear Therapeutics
• Spirogen
• SRI International
• Stemline Therapeutics
• SuperGen
• Swedish Orphan Biovitrum
• Switch Pharma
• SymBio Pharmaceuticals
• Symbiotec
• Synageva BioPharma
• SynDevRx
• Synta Pharmaceuticals
• Syntrix
• Takeda
• Talon Therapeutics
• TapImmune
• Targa Therapeutics
• TargeGen
• Tau Therapeutics
• TeGenero
• Teva
• Therion Biologics
• ThromboGenics
• Tigris Pharmaceuticals
• ToolGen
• TopoTarget
• Tracon Pharmaceuticals
• Transgene
• Trion Pharma
• UCB
• United Biomedical
• Vaccinex
• Valeant
• Vaxil BioTherapeutics
• Vaxon Biotech
• VaxOnco
• VBL Therapeutics
• Vectura
• Vertex Pharmaceuticals
• Vical
• Wilex
• Vion Pharmaceuticals
• VioQuest Pharmaceuticals
• Viragen
• Virionics
• ViroMed
• Wyeth
• XBiotech
• Xencor
• Xerion
• Yamasa Corporation
• Zensun
• Zenyaku Kogyo
• A Shortlist of Drugs Included are:
• ADXS11-001
• AE-37
• aflibercept
• alemtuzumab
• ALVAC-CEA/B7.1
• amonafide malate
• amsacrine
• apatinib
• ARQ-197
• astuprotimut-r
• AVX-701
• axitinib
• barasertib
• belagenpumatucel-L
• belinostat
• bevacizumab
• BIBF-1120
• bisantrene
• bosutinib
• BP-GMAX-CD1
• brivanib alaninate
• Cadi-05
• CB-10-01
• CEA-TRICOM
• cediranib
• CG-201
• cilengitide
• cladribine
• clofarabine
• CMLVAX-100
• CSF-GM
• CTL901
• CTP-37
• CVac
• cytarabine ocfosfate
• cytarabine, injectable
• dasatinib
• daunorubicin
• DCVax-prostate
• decitabine
• E-75
• elacytarabine
• endostatin
• enocitabine
• enzastaurin hydrochloride
• everolimus
• fosbretabulin tromethamine
• fowlpox-PSA vaccine
• gemtuzumab ozogamicin
• GRNVAC1
• GV-1001
• GV-1002
• GVAX
• GVX-3322
• HBP-347
• Her-2/Neu peptides
• histamine dihydrochloride
• idarubicin
• IGN-101
• imatinib mesilate
• ImmunoVEX tri-melan
• IMO-2055
• INGN-225
• INGN-241
• interferon
• interferon (alpha-N1)
• interferon (alpha)
• interferon (alpha2)
• interferon (alpha2a)
• interferon (alpha2b)
• interferon (alpha2c)
• interferon (gamma)
• interferon alpha-2b
• lestaurtinib
• leukemia vaccine
• linifanib
• lumiliximab
• MAGE-3-TK
• ME-103
• MGN-1601
• midostaurin
• mitoxantrone
• motesanib diphosphate
• MSI vaccine
• MVA-BN
• MVA-BN Her-2 vaccine
• nilotinib
• Norelin
• obinutuzumab
• oblimersen sodium
• ofatumumab
• ON-01910
• Onyvax-105
• OTS-102
• PANVAC-VF
• patupilone
• pazopanib hydrochloride
• pDOM-PSMA27
• peginterferon alfa-2b
• pentostatin
• PEP-223
• poly-ICLC
• PR1:169-177 peptide
• PROSTVAC
• PX-104.1
• ramucirumab
• razoxane
• Reximmune-C
• rhIFN-alpha
• ridaforolimus
• rindopepimut
• rituximab
• SAI-EGF
• sobuzoxane
• sorafenib tosylate
• Stimuvax
• sunitinib malate
• talactoferrin alfa
• tamibarotene
• teniposide
• TG-4001
• TG-4010
• thymalfasin
• tipifarnib
• TroVax
• vandetanib
• verpasep caltespen
• vosaroxin
• VX-001
• XL-184
• zorubicin
• ZYC-300

相關商品

癌症相關市場調查報告書

膀胱癌相關的各種合作趨勢:2007-2012年
Bladder Cancer Partnering 2007-2012
價格 : US $ 995
出版日期 : 2012年05月

腦瘤相關的各種合作趨勢:2007-2012年
Brain Cancer Partnering 2007-2012
價格 : US $ 995
出版日期 : 2012年05月

乳癌相關的各種合作趨勢:2007-2012年
Breast Cancer Partnering 2007-2012
價格 : US $ 1695
出版日期 : 2012年05月

BioSeeker Group AB發行的製藥相關市場調查報告書

癌症的蛋白激脢治療上的競爭分析

Competitive Insights to Protein Kinase Therapeutics in Oncology: The Faster Route to Consider Your Options and Position of Others

價格 : US $ 4425

出版日期 : 2012年05月

分析工具：癌症治療的蛋白激脢抗化劑

Analytical Tool - Protein Kinase Inhibitors in Oncology

價格 : US $ 6674

出版日期 : 2012年05月

乳癌、大腸癌、蛋白質激酶抑制劑分析

Triple Analysis: Breast Cancer, Colorectal Cancer and Protein Kinase Inhibitors

價格 : US $ 5175

出版日期 : 2012年05月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!